Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cyrille Touzeau

Showing results (1-10 of 205) with videos related to

Pageof 21
Sort By:
The Lancet. Haematology|May 13, 2022
Elotuzumab: no benefit for older patients with newly diagnosed multiple myelomaCyrille Touzeau
Blood|January 17, 2025
Daratumumab for maintenance in myelomaCyrille Touzeau, Aurore Perrot
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Multiple myeloma: from front-line to relapsed therapiesPhilippe Moreau, Cyrille Touzeau
Blood|April 16, 2026
Does minimal residual disease matter in t(11;14) myeloma?Cyrille Touzeau, Jill Corre
Blood|December 19, 2015
How I treat extramedullary myelomaCyrille Touzeau, Philippe Moreau
Seminars in Oncology|October 19, 2013
Initial treatment of transplant candidates with multiple myelomaPhilippe Moreau, Cyrille Touzeau
Future Oncology (London, England)|June 11, 2016
Pomalidomide in the management of relapsed multiple myelomaCyrille Touzeau, Philippe Moreau
Blood|July 1, 2021
Sensitivity to venetoclax: the B-side of myeloma?Cyrille Touzeau, Philippe Moreau
Expert Opinion on Biological Therapy|April 25, 2017
Daratumumab for the treatment of multiple myelomaCyrille Touzeau, Philippe Moreau
Acta Haematologica|July 5, 2014
New data on subcutaneous bortezomibPhilippe Moreau, Cyrille Touzeau
Pageof 21

Showing results (1-10 of 205) with videos related to

Sort By:
Pageof 21
The Lancet. Haematology|May 13, 2022
Elotuzumab: no benefit for older patients with newly diagnosed multiple myelomaCyrille Touzeau
Blood|January 17, 2025
Daratumumab for maintenance in myelomaCyrille Touzeau, Aurore Perrot
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Multiple myeloma: from front-line to relapsed therapiesPhilippe Moreau, Cyrille Touzeau
Blood|April 16, 2026
Does minimal residual disease matter in t(11;14) myeloma?Cyrille Touzeau, Jill Corre
Blood|December 19, 2015
How I treat extramedullary myelomaCyrille Touzeau, Philippe Moreau
Seminars in Oncology|October 19, 2013
Initial treatment of transplant candidates with multiple myelomaPhilippe Moreau, Cyrille Touzeau
Future Oncology (London, England)|June 11, 2016
Pomalidomide in the management of relapsed multiple myelomaCyrille Touzeau, Philippe Moreau
Blood|July 1, 2021
Sensitivity to venetoclax: the B-side of myeloma?Cyrille Touzeau, Philippe Moreau
Expert Opinion on Biological Therapy|April 25, 2017
Daratumumab for the treatment of multiple myelomaCyrille Touzeau, Philippe Moreau
Acta Haematologica|July 5, 2014
New data on subcutaneous bortezomibPhilippe Moreau, Cyrille Touzeau
Pageof 21